{"altmetric_id":4872876,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["ConcordeMedica"],"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4ee3cf058f610002c37","doi":"10.1097\/qai.0000000000000916","first_seen_on":"2015-12-14T00:03:52+00:00","issns":["1525-4135"],"issue":"1","journal":"JAIDS: Journal of Acquired Immune Deficiency Syndromes","last_mentioned_on":1450051417,"links":["http:\/\/journals.lww.com\/jaids\/Fulltext\/2016\/01010\/Dolutegravir_Plus_Abacavir_Lamivudine_for_the.21.aspx"],"pdf_url":"http:\/\/pdfs.journals.lww.com\/jaids\/2016\/01010\/Dolutegravir_Plus_Abacavir_Lamivudine_for_the.21.pdf","pubdate":"2016-01-01T00:00:00+00:00","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"e33","subjects":["acquiredimmunodeficiencysyndrome"],"title":"Dolutegravir Plus Abacavir\/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial: Erratum","type":"article","volume":"71"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":6756570,"mean":6.169004694245,"rank":5776088,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":6756570,"percentile":1},"similar_age_3m":{"total_number_of_other_articles":286774,"mean":8.6699113933319,"rank":231642,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":286774,"percentile":1},"this_journal":{"total_number_of_other_articles":1799,"mean":3.3836229143493,"rank":1639,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":1799,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":48,"mean":1.7627659574468,"rank":43,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":48,"percentile":1}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}}},"geo":{"twitter":{"GB":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/ConcordeMedica\/statuses\/676190769984720896","license":"gnip","citation_ids":[4872876],"posted_on":"2015-12-14T00:03:37+00:00","author":{"name":"Dr Alex Concorde","url":"http:\/\/www.dralexconcorde.info\/#!health-and-medicine\/c224f","image":"https:\/\/pbs.twimg.com\/profile_images\/1248165228\/concorde_medica_cropped__normal.jpg","description":"Dr Alex is creator of a unique 21C Individual Medicine called 'CruX'! This New Paradigm precisely identifies & targets mind\/-body pathways causing unwellness.","id_on_source":"ConcordeMedica","tweeter_id":"250807966","geo":{"lt":54.75844,"ln":-2.69531,"country":"GB"},"followers":3792},"tweet_id":"676190769984720896"}]}}